<DOC>
	<DOCNO>NCT00079170</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . It yet know whether garlic supplement affect ability docetaxel kill tumor cell . PURPOSE : This clinical trial study well give docetaxel together garlic work treat patient locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Plus Garlic Treating Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical pharmacokinetic behavior docetaxel without garlic tablet patient locally advance metastatic breast cancer . - Determine toxicity regimen patient . Secondary - Determine incidence enzyme transporter polymorphism patient treat regimen . OUTLINE : This pilot , open-label study . Patients receive docetaxel IV 60 minute day 1 , 8 , 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . On day 5-17 course 1 , patient receive oral garlic twice daily . Patients option continue garlic tablet long remain study . PROJECTED ACCRUAL : A total 9-12 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Incurable , locally advanced metastatic disease therapy docetaxel reasonable option No documentation progressive disease docetaxel within past 2 month Brain and/or leptomeningeal metastasis allow follow criterion meet : Asymptomatic neurological examination , include definitive radiotherapy No corticosteroid therapy control symptom Stable lesion Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal Status Not specify Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Neutrophil count ≥ 1,200/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal ALT AST ≤ 2 time ULN ( 3 time ULN liver metastasis ) Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal No known gastric empty disorder No persistent diarrhea Other No uncontrolled diabetes mellitus No active infection No prior grade 3 4 allergic reaction attribute compound similar biological composition garlic , docetaxel , Tween 80 No concurrent uncontrolled medical condition would preclude study participation No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception Must able ingest oral medication Lactic dehydrogenase ≤ 2 time ULN PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 week since prior immunotherapy No concurrent immunotherapy Trastuzumab ( Herceptin® ) allow first course therapy discretion primary physician No concurrent pegfilgrastim Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 2 week since prior hormonal therapy No concurrent hormonal therapy No concurrent megestrol first course study treatment Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 30 day ( 5 halflives ) since prior investigational therapy No concurrent aprepitant ( Emend® ) No concurrent oral tetrahydrocannabinol ( Marinol® ) first course study treatment No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational anticancer medication No concurrent antiepileptic therapy No concurrent immunosuppressants No concurrent herbal therapy first month study participation No concurrent grapefruit juice first month study participation No concurrent administration follow : Alprazolam Cyclosporine Diltiazem Dofetilide Erythromycin Fluvoxamine Itraconazole Ketoconazole Quinine Hypericum perforatum ( St. John 's wort ) Tacrolimus Theophylline Warfarin Zolpidem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>